
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx Inc has demonstrated a positive outlook due to its strategic investments in the ArdelyxAssist patient assistance program and its salesforce, which are expected to enhance prescription volumes and patient engagement, particularly for the XPHOZAH product. Financial projections are favorable, with revenue estimates for IBSRELA anticipated to reach $422 million in FY26 and $878 million in FY29, reflecting growth potential that exceeds consensus expectations. Additionally, clinical data indicates effective treatment outcomes for patients with severe constipation, further supporting the efficacy of Ardelyx's therapeutic offerings.
Bears say
Ardelyx Inc. is experiencing declining gross-to-net (GTN) margins for its product Ibsrela, which fell to 31% in Q3 2025 from 32.2% in Q2 2025, indicating potential pricing pressures and diminishing profitability. Despite the reported efficacy of Xphozah in reducing serum phosphate levels, the company faces threats from potential changes to reimbursement pricing structures that could adversely affect sales. Furthermore, the ambitious peak net sales guidance of over $1 billion for Ibsrela appears unrealistic given current market conditions, compounded by the risk of failing to secure crucial product labels that could restrict market traction.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares